siRNA for inhibiting ADAM17 (a disintegrin and metalloprotease 17) genes and application of siRNA

A DNA molecule, methoxyl modification technology, applied in DNA/RNA fragments, recombinant DNA technology, medical preparations containing active ingredients, etc., can solve problems such as differences in silencing effect

Inactive Publication Date: 2015-04-08
GUANGZHOU RIBOBIO +1
View PDF4 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, a variety of siRNAs can be designed for different fragment positi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • siRNA for inhibiting ADAM17 (a disintegrin and metalloprotease 17) genes and application of siRNA
  • siRNA for inhibiting ADAM17 (a disintegrin and metalloprotease 17) genes and application of siRNA
  • siRNA for inhibiting ADAM17 (a disintegrin and metalloprotease 17) genes and application of siRNA

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0090] Embodiment 1, the screening of the effective oligonucleotide that suppresses ADAM17 gene mRNA expression

[0091] 1. Perform siRNA design to determine siRNAs targeting ADAM17, and perform bioinformatic screening to ensure that the sequence is specific to the ADAM17 sequence and not specific to sequences from any other gene. The target sequence was checked against the sequence in GenBank using the BLAST search engine provided by NCBI. After preliminary experiments, 8 effective siRNAs were screened out, named siRNA-AD-01, siRNA-AD-02, siRNA-AD-03, and siRNA respectively. - AD-04, siRNA-AD-05, siRNA-AD-06, siRNA-AD-07, siRNA-AD-08. The above siRNAs are siRNAs designed for different positions of the ADAM17 gene sequence.

[0092] 2. Cell transfection

[0093] The experiment was divided into 10 groups, namely siRNA-AD-01 to siRNA-AD-08 experimental groups, Notarget (NTC) was the negative control group, and NC was the blank control group.

[0094] The setting method of siR...

Embodiment 2

[0113] Embodiment 2, the inhibition of oligomeric nucleic acid to inflammatory factor

[0114] 1. The experiment is divided into the following groups:

[0115] hFLS-siRNA-AD-08 experimental group: primary culture hFLS cells to 6-well plate, when the cell density was about 50%, according to Lipofectamine2000 kit instructions, transfect hFLS cells with siRNA-AD-08 at a final concentration of 50nM.

[0116] MCF-7-siRNA-AD-08 experimental group: primary culture MCF-7 cells to 6-well plate, when the cell density is about 50%, according to Lipofectamine2000 kit instructions, transfer siRNA-AD-08 according to the final concentration of 50nM Infect MCF-7 cells.

[0117] hFLS-No target (NTC) negative control group: replace the siRNA in the hFLS-siRNA-AD-08 experimental group with random non-specific siRNA, and the rest of the steps remain unchanged. Among them, the random non-specific siRNA is not specific to the siRNA designed for the target gene (ADAM17 gene):

[0118] Sense stran...

Embodiment 3

[0144] Example 3, verification of homologous oligonucleotides on ADAM17 gene inhibitory effect

[0145] In order to verify the influence of the homology ratio on the effect of siRNA-AD-08 on suppressing the ADAM17 gene, the following three sets of experiments were carried out:

[0146] 1. The first set of experiments

[0147] The siRNA antisense strands of the first group are all "5'-UUGUUCAGAUACAUGAUGC-3'"

[0148] , the sense strand is the homologous sequence of "5'-GCAUCAUGUAUCUGAACAA-3'", as shown in Table 1.

[0149] Table 1 Antisense strand group

[0150]

[0151] Note: S=sense strand, AS=antisense strand. Choose 11nt, 15nt, 23nt, 27nt, and mismatches for the sense strands, respectively.

[0152] According to the method of Example 1, each siRNA shown in Table 1 was transfected into hFLS cells, and its inhibitory efficiency on ADAM17 gene mRNA expression was detected.

[0153] 2. The second set of experiments

[0154] The sense strands of the second group of siRN...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a siRNA for inhibiting ADAM17 (a disintegrin and metalloprotease 17) genes and an application of the siRNA. The invention discloses a chemically-modified dual-chain siRNA molecule, and particularly relates to a dual-chain siRNA molecule which is formed by chemically modifying and supplementing (as shown in (1) to (13)) at least one chain in the siRNA molecule indicated by A. The siRNA can be used as a treatment drug for arthritis and relevant inflammations, and the siRNA and preparations of the siRNA can be locally injected through a bone joint cavity to inhibit the inflammation factor expression so as to realize the treatment for the arthritis.

Description

technical field [0001] The invention relates to siRNA for inhibiting ADAM17 gene and application thereof, belonging to the field of biotechnology. Background technique [0002] Osteoarthritis (OA) is a chronic degenerative bone and joint disease that seriously endangers human health. At present, there is no effective treatment. There is an urgent need to develop new methods that can effectively prevent and treat osteoarthritis. One of the clinicopathological features of osteoarthritis is cartilage destruction and hFLS extracellular matrix degradation, and cartilage destruction is ultimately derived from the proteolysis of extracellular matrix. Therefore, the abnormal degradation of the secondary extracellular matrix (ECM) caused by the increased activity of various proteolytic enzymes is the direct cause of cartilage degeneration, which eventually leads to the destruction of the cartilage covering the surface of articular bone. Both interleukin-1 (IL-1) and tumor necrosis f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N15/113A61K31/713A61P29/00A61P19/02A61P19/04A61P17/06A61P37/02
Inventor 张必良米其·托尔托雷王喆杨秀群王秋云
Owner GUANGZHOU RIBOBIO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap